A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi, n=24; IL-17, n=13) Most of the SMDs were small --> b/tsDMARDs showed small to moderate effects on peripheral arthritis & enthesitis. #ACR25 @RheumNow Abs0588 https://t.co/yGXcqhZ1Uv

• https://x.com/RHEUMarampa/status/1982490153852833879/photo/1

#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ

• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1
• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1

Novelli et al. Upadacitinib in male vs female PsA. Data from SELECT-PsA studies. Appears equivalent in males and females, contrasting with TNFi/IL17i data. @RheumNow #ACR25 Abstr#557 https://t.co/fMKsbCkju0

• https://x.com/RichardPAConway/status/1982482604373787008/photo/1

2-Year data from SELECT-GCA Phase 3 UPA in GCA Re-randomization & 52 weeks extension UPA 15mg vs. PBO -Risk of flare 90% lower -Complete remission 70% vs 20% -Cumulative GC 1g difference -No new safety signal The quick relapse after stopping UPA indicates we are really looking https://t.co/c1khywnPNv

• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1
• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1

Immune-Mediated Necrotizing Myopathy @EleniTiniakou #ACR25 *Younger pts tend to have a more aggressive disease *IVIG and RTX can be considered first-line rx for anti-HMGCR and anti-SRP+, respectively *CYC and plasmapheresis may be options in cases of aggressive disease https://t.co/zWDX79gqlf

• https://x.com/RheumQuarterly/status/1982461272500097265/photo/1

Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm

• https://x.com/RichardPAConway/status/1982477067988992375/photo/1

SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue upa? Extension data (second year) flare survival curves are clear: continuing upa far outperforms placebo It seems >2y toci/upa for GCA #ACR25 ABST0776 @RheumNow https://t.co/uJA3uQyWxb

• https://x.com/drdavidliew/status/1982476822744121513/photo/1

#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g. No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q

• https://x.com/DrMiniDey/status/1982476564739620938/photo/1

#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83

• SLE Conference Preview: progress in biologics | RheumNow
• https://x.com/Yuz6Yusof/status/1982466449328189855/photo/1

Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z

• Positive CHMP opinion for subcutaneous Saphnelo